News

Altimmune Posts Positive Interim Weight Loss Results in Phase 1 ALT-801 Trial

June 17, 2021 (Investorideas.com Newswire) Altimmune Inc. shares traded 16% higher after the company reported positive interim data from a Phase 1 study of ALT-801 in overweight and obese trial participants.

What's your reaction?

Excited
0
Happy
0
In Love
0
Not Sure
0
Silly
0

You may also like

Leave a reply

Your email address will not be published. Required fields are marked *

More in:News